Large B Cell Lymphoma

Also known as: Large B-cell Lymphoma

Drug	Drug Name	Drug Description
DB16371	Glofitamab	A bispecific monoclonal antibody directed against CD20 and CD3 which is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
DB12240	Polatuzumab vedotin	A CD79b antibody conjugate indicated to treat different types of large B-cell lymphoma.

Drug	Drug Name	Target	Type
DB16371	Glofitamab	B-lymphocyte antigen CD20	target
DB16371	Glofitamab	T-cell surface glycoprotein CD3	target
DB12240	Polatuzumab vedotin	Cytochrome P450 3A4	enzyme
DB12240	Polatuzumab vedotin	B-cell antigen receptor complex-associated protein beta chain	target
DB12240	Polatuzumab vedotin	P-glycoprotein 1	transporter
DB12240	Polatuzumab vedotin	Cytochrome P450 3A5	enzyme

Drug	Drug Name	Phase	Status	Count
DB13915	Axicabtagene ciloleucel	1	Recruiting	1
DB00531	Cyclophosphamide	1	Not Yet Recruiting	1
DB00531	Cyclophosphamide	1	Recruiting	1
DB01073	Fludarabine	1	Not Yet Recruiting	1
DB01073	Fludarabine	1	Recruiting	1
DB01008	Busulfan	1 / 2	Active Not Recruiting	1
DB00441	Gemcitabine	1 / 2	Active Not Recruiting	1
DB09053	Ibrutinib	1 / 2	Recruiting	1
DB18356	Inaticabtagene Autoleucel	1 / 2	Active Not Recruiting	1
DB01042	Melphalan	1 / 2	Active Not Recruiting	1
DB00531	Cyclophosphamide	2	Recruiting	1
DB00531	Cyclophosphamide	2	Unknown Status	1
DB00997	Doxorubicin	2	Unknown Status	1
DB16672	Epcoritamab	2	Recruiting	1
DB00773	Etoposide	2	Unknown Status	1
DB00099	Filgrastim	2	Unknown Status	1
DB16371	Glofitamab	2	Not Yet Recruiting	1
DB16371	Glofitamab	2	Recruiting	1
DB16222	Loncastuximab tesirine	2	Recruiting	1
DB16225	Magrolimab	2	Withdrawn	1
DB15434	Mosunetuzumab	2	Recruiting	1
DB08935	Obinutuzumab	2	Not Yet Recruiting	1
DB08935	Obinutuzumab	2	Recruiting	1
DB12240	Polatuzumab vedotin	2	Not Yet Recruiting	1
DB00635	Prednisone	2	Recruiting	1
DB00635	Prednisone	2	Unknown Status	1
DB00073	Rituximab	2	Recruiting	1
DB00073	Rituximab	2	Unknown Status	1
DB00073	Rituximab	2	Withdrawn	1
DB14922	Tislelizumab	2	Not Yet Recruiting	1
DB00541	Vincristine	2	Recruiting	1
DB00541	Vincristine	2	Unknown Status	1
DB15035	Zanubrutinib	2	Not Yet Recruiting	1
DB11703	Acalabrutinib	3	Recruiting	1
DB00531	Cyclophosphamide	3	Completed	1
DB00531	Cyclophosphamide	3	Not Yet Recruiting	1
DB00531	Cyclophosphamide	3	Recruiting	1
DB00997	Doxorubicin	3	Completed	1
DB00997	Doxorubicin	3	Not Yet Recruiting	1
DB00997	Doxorubicin	3	Recruiting	1
DB00773	Etoposide	3	Completed	1
DB00099	Filgrastim	3	Completed	1
DB16371	Glofitamab	3	Recruiting	1
DB18115	Golcadomide	3	Not Yet Recruiting	1
DB00480	Lenalidomide	3	Recruiting	1
DB00019	Pegfilgrastim	3	Completed	1
DB12240	Polatuzumab vedotin	3	Recruiting	1
DB00635	Prednisone	3	Completed	1
DB00635	Prednisone	3	Not Yet Recruiting	1
DB00635	Prednisone	3	Recruiting	1
DB00073	Rituximab	3	Completed	1
DB00073	Rituximab	3	Not Yet Recruiting	1
DB00073	Rituximab	3	Recruiting	1
DB15044	Tafasitamab	3	Recruiting	1
DB00541	Vincristine	3	Completed	1
DB00541	Vincristine	3	Not Yet Recruiting	1
DB13915	Axicabtagene ciloleucel	Not Available	Active Not Recruiting	1
DB13915	Axicabtagene ciloleucel	Not Available	Available	1
DB15699	Brexucabtagene autoleucel	Not Available	Active Not Recruiting	1
DB00531	Cyclophosphamide	Not Available	Active Not Recruiting	1
DB16672	Epcoritamab	Not Available	Approved for Marketing	1
DB01073	Fludarabine	Not Available	Active Not Recruiting	1
DB16665	Idecabtagene vicleucel	Not Available	Active Not Recruiting	1
DB16582	Lisocabtagene maraleucel	Not Available	Active Not Recruiting	1
DB13881	Tisagenlecleucel	Not Available	Active Not Recruiting	1